| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg | |||
| Other Sizes |
| Targets |
TMC353121 targets the RSV fusion protein, which is essential for the entry of the virus into host cells. By inhibiting the fusion protein, TMC353121 prevents the virus from fusing with the host cell membrane, thereby blocking viral entry and replication. The compound's activity profile was found to be identical to the profile of JNJ-2408068.
|
|---|---|
| ln Vitro |
TMC353121 shown effectiveness against a panel of clinical isolates with comparable potency as well as group A and group B RSV [1]. A strong in vitro RSV fusion inhibitor is TMC353121. In HeLaM cells, TMC353121 exhibits 50% effective concentration (EC50) of 0.07 ng/mL against wild-type RSV (LO strain) [2].
TMC353121 is a potent RSV fusion inhibitor in vitro. It shows activity against groups A and B RSV and against a panel of clinical isolates with equal potency. It also inhibits the production of inflammatory cytokines TNF-α, IL-6, and IL-1β, as well as chemokines KC, IP-10, and MIP1-α. These in vitro studies confirm the compound's potent antiviral and anti-inflammatory activity. |
| ln Vivo |
After giving Sprague-Dawley rats a single intravenous bolus dosage of 10 mg/kg, TMC353121's plasma concentration-time profile showed multicompartmental pharmacokinetics. The final part of the curve, which shows the mean plasma drug concentrations between 8 and 24 hours after dose, shows that the drug concentrations decrease quickly in the first few hours after dosing and then more slowly, with a half-life of about 12 hours. With a clearance rate of 8.6 L/h/kg and a distribution width of 55 L/kg, TMC353121 is rapidly removed from plasma [2]. Two injections of TMC353121, at a dose of 2.5 mg/kg or 0.25 mg/kg, are given intravenously once. Serum, bronchoalveolar lavage fluid, and lung tissue drug concentrations were assessed at various times. When administered intravenously, TMC353121 exhibits multicompartmental pharmacokinetics, meaning that its serum concentration rapidly decreases within the first hour and then slowly declines over the next hour. After a day, the drug's blood levels are extremely low due to its rapid excretion from the body. The drug was marginally above the detection limit in BAL fluid eight hours after injection, and pulmonary concentrations were significantly greater than serum concentrations.
In vivo, TMC353121 has been studied in preclinical models of RSV infection. After intravenous bolus administration of a single dose of 10 mg/kg to Sprague-Dawley rats, the plasma drug concentration-time profile exhibits multicompartmental pharmacokinetics. The compound is rapidly eliminated from plasma (CL=8.6 liters/h/kg) and extensively distributed (Vss=55 liters/kg). Lung concentrations are much higher than serum concentrations. |
| Enzyme Assay |
TMC353121's activity is typically measured using in vitro antiviral assays. In a typical assay, HeLaM cells are infected with RSV and treated with varying concentrations of TMC353121. Viral replication is quantified by measuring the levels of viral RNA or by plaque assay. The EC50 is determined from dose-response curves.
|
| Cell Assay |
In vitro cell-based assays for TMC353121 are conducted using HeLaM cells or other susceptible cell lines infected with RSV. Cells are treated with the compound at various concentrations, and viral replication is measured. The compound's ability to inhibit viral replication and to reduce the production of inflammatory cytokines is assessed.
|
| Animal Protocol |
In vivo animal experiments for TMC353121 have been conducted in preclinical models of RSV infection. In a typical study, the compound is administered intravenously to animals infected with RSV. Viral load in the lungs and other tissues is measured. The compound's ability to reduce viral load and to improve clinical outcomes is assessed.
|
| ADME/Pharmacokinetics |
TMC353121 has a molecular weight of 558.71 g/mol and a molecular formula of C32H42N6O3. It has a CAS number of 857066-90-1. It is a pink to red solid with a purity of >98%. It is soluble in DMSO. For storage, it is recommended to keep the powder at -20°C for up to 3 years or at 4°C for up to 2 years. In solvent, it can be stored at -80°C for 6 months or at -20°C for 1 month.
|
| Toxicity/Toxicokinetics |
Detailed toxicity data for TMC353121 is not provided in standard product descriptions. As a research compound, its toxicity profile has not been extensively characterized. In vivo studies have used TMC353121 at doses that are effective in reducing viral load without reported overt toxicity. However, comprehensive toxicological studies have not been reported. As with all research chemicals, standard laboratory safety precautions should be followed.
|
| References |
|
| Additional Infomation |
TMC353121 is a research compound and is not approved for any clinical or therapeutic use. It is a potent RSV fusion inhibitor with a pEC50 of 9.9. It is active against wild-type RSV with an EC50 of 0.07 ng/mL in HeLaM cells. TMC353121 also inhibits the production of inflammatory cytokines. It is a valuable research tool for studying RSV infection and for developing new antiviral therapies.
|
| Molecular Formula |
C32H42N6O3
|
|---|---|
| Molecular Weight |
558.727
|
| Exact Mass |
558.332
|
| CAS # |
857066-90-1
|
| Related CAS # |
857066-90-1
|
| PubChem CID |
11249932
|
| Appearance |
Pink to red solid powder
|
| LogP |
3.906
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
13
|
| Heavy Atom Count |
41
|
| Complexity |
757
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
DKORMNNYNRPTBJ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C32H42N6O3/c1-23-6-9-26(5-3-16-39)28(19-23)34-21-25-8-10-27-30(20-25)38(22-29-31(40)11-7-24(2)35-29)32(36-27)33-12-4-13-37-14-17-41-18-15-37/h6-11,19-20,34,39-40H,3-5,12-18,21-22H2,1-2H3,(H,33,36)
|
| Chemical Name |
2-[[6-[[2-(3-hydroxypropyl)-5-methylanilino]methyl]-2-(3-morpholin-4-ylpropylamino)benzimidazol-1-yl]methyl]-6-methylpyridin-3-ol
|
| Synonyms |
TMC-353121 TMC353121 TMC 353121
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~50 mg/mL (~89.49 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (4.47 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 2.5 mg/mL (4.47 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (4.47 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.7898 mL | 8.9489 mL | 17.8977 mL | |
| 5 mM | 0.3580 mL | 1.7898 mL | 3.5795 mL | |
| 10 mM | 0.1790 mL | 0.8949 mL | 1.7898 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
|
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
